Results 3,141-3,160 of 16,478 for speaker:Tommy Broughan

Written Answers — Department of Health: General Practitioner Services (21 Nov 2017)

Tommy Broughan: 322. To ask the Minister for Health if it is permissible for general practitioners to charge small fees to persons with medical cards for certain services or weekend visits; if not, the way in which this practice is being monitored to ensure that it is not commonplace; and if he will make a statement on the matter. [48740/17]

Written Answers — Department of Health: Mental Health Services (21 Nov 2017)

Tommy Broughan: 323. To ask the Minister for Health when the 24-7 crisis mental health service will be launched as announced in February 2017; and if he will make a statement on the matter. [48757/17]

Written Answers — Department of Health: Vaccination Programme (21 Nov 2017)

Tommy Broughan: 326. To ask the Minister for Health if he will report on the alleged inclusion of thiomersal in the influenza vaccine being administered by the HSE; if his Department and the HSE are studying reports of increased instances of miscarriage allegedly due to this substance; and if he will make a statement on the matter. [48790/17]

Written Answers — Department of Health: Vaccination Programme (21 Nov 2017)

Tommy Broughan: 327. To ask the Minister for Health if all elements used in the HSE influenza vaccine are safe for pregnant persons; the evidence his Department and the HSE have to support this; if recent conflicting evidence is being examined; and if he will make a statement on the matter. [48791/17]

Written Answers — Department of Transport, Tourism and Sport: National Transport Authority Administration (21 Nov 2017)

Tommy Broughan: 503. To ask the Minister for Transport, Tourism and Sport the direction he has given to the National Transport Authority regarding liaising with taxi drivers in Dublin in view of the changes to access in Dublin city centre due to the Luas cross city project; and if he will make a statement on the matter. [48755/17]

Written Answers — Department of Employment Affairs and Social Protection: Rent Supplement Scheme (21 Nov 2017)

Tommy Broughan: 564. To ask the Minister for Employment Affairs and Social Protection the number of persons under 18 years of age with severe physical disabilities and living in their family home whose family was in receipt of rent supplement in each of the years 2014 to 2016 and to date in 2017 (details supplied); and if she will make a statement on the matter. [48758/17]

Written Answers — Department of Housing, Planning, and Local Government: Social and Affordable Housing Data (21 Nov 2017)

Tommy Broughan: 607. To ask the Minister for Housing, Planning, and Local Government to set out the number of persons under 18 years of age with severe physical disabilities who are living in the family home in which the family is in receipt of HAP or RAS payments in each of the years 2014 to 2016 and to date in 2017 (details supplied); and if he will make a statement on the matter. [48758/17]

Written Answers — Department of Housing, Planning, and Local Government: Social and Affordable Housing Data (21 Nov 2017)

Tommy Broughan: 642. To ask the Minister for Housing, Planning, and Local Government further to Parliamentary Question No. 518 of 14 of November 2017 if persons with a social housing need remain entitled to RAS; if local authorities have a statutory obligation to approve a person for RAS once a landlord who is willing to enter the RAS has been identified; and if he will make a statement on the matter. [49329/17]

Written Answers — Department of Housing, Planning, and Local Government: Social and Affordable Housing Data (21 Nov 2017)

Tommy Broughan: 643. To ask the Minister for Housing, Planning, and Local Government further to Parliamentary Question No. 518 of 14 November 2017 if the €134 million provided in budget 2018 to support a further 600 new transfers under RAS is for new RAS tenancies or for tenancies transferring out of RAS; and if he will make a statement on the matter. [49330/17]

Written Answers — Department of Housing, Planning, and Local Government: Social and Affordable Housing Data (21 Nov 2017)

Tommy Broughan: 644. To ask the Minister for Housing, Planning, and Local Government further to Parliamentary Question No. 518 of 14 November 2017 if all sections of the legislation underpinning RAS have been commenced; the legal entitlement of persons in need of social housing support to access RAS; and if he will make a statement on the matter. [49331/17]

Written Answers — Department of Housing, Planning, and Local Government: Social and Affordable Housing Data (21 Nov 2017)

Tommy Broughan: 645. To ask the Minister for Housing, Planning, and Local Government to outline the differences between RAS tenancies post-1 April 2011 and HAP tenancies; the differences between RAS tenancies that were in place prior to 1 April 2011 and HAP tenancies; and if he will make a statement on the matter. [49332/17]

Written Answers — Department of Housing, Planning, and Local Government: Land Availability (21 Nov 2017)

Tommy Broughan: 641. To ask the Minister for Housing, Planning, and Local Government further to Parliamentary Question No. 514 of 14 of November 2017, the local authorities that have submitted plans for development of their sites; those which have yet to submit their plans; the timeframe for those plans to be published and implemented; and if he will make a statement on the matter. [49328/17]

Written Answers — Department of Agriculture, Food and the Marine: Greyhound Industry (16 Nov 2017)

Tommy Broughan: 167. To ask the Minister for Agriculture, Food and the Marine the number of veterinary inspections at clubs (details supplied) in 2015, 2016 and to date in 2017; and if he will make a statement on the matter. [47710/17]

Ceisteanna - Questions (Resumed) - Priority Questions: Medicinal Products Supply (15 Nov 2017)

Tommy Broughan: I welcome the comments on the quality-of-life criteria for all rare diseases. The National Centre for Pharmacoeconomics report seems to make it clear that on clinical grounds there is a positive approach. As the Minister has said, it seems to come down to the economics and the difficulty of measuring costings for a very small cohort. Like the Minister, I am very familiar with this...

Ceisteanna - Questions (Resumed) - Priority Questions: Medicinal Products Supply (15 Nov 2017)

Tommy Broughan: Many parents have outlined their daily struggle and the greater freedom-----

Ceisteanna - Questions (Resumed) - Priority Questions: Medicinal Products Supply (15 Nov 2017)

Tommy Broughan: ----- having access to a wider protein diet would have-----

Ceisteanna - Questions (Resumed) - Priority Questions: Medicinal Products Supply (15 Nov 2017)

Tommy Broughan: ----- if Kuvan were authorised. I know the Minister is sympathetic, but we need to act soon.

Ceisteanna - Questions (Resumed) - Priority Questions: Medicinal Products Supply (15 Nov 2017)

Tommy Broughan: The cost outlined in the report for 100% uptake is relatively tiny in the health budget at €12.7 million over five years or €2.5 million a year. The European PKU society which has strongly supported the PKU Association of Ireland has made the basic point that the EU regulatory agencies approved the drug in 2009 for use in 20 European countries at the time. A range of our...

Ceisteanna - Questions (Resumed) - Priority Questions: Medicinal Products Supply (15 Nov 2017)

Tommy Broughan: 25. To ask the Minister for Health the status of the HSE's approval process for the health technology assessment report from the National Centre for Pharmacoeconomics, NCPE, on the drug Kuvan, which is used to treat persons with phenylketonuria; when he expects the drug to be approved for treatment of these persons; and if he will make a statement on the matter. [48283/17]

Ceisteanna - Questions (Resumed) - Priority Questions: Medicinal Products Supply (15 Nov 2017)

Tommy Broughan: The Minister is very familiar with the rare genetic disease phenylketonuria where patients have difficulty processing the amino acid phenylalanine and therefore must live on very restricted, low-protein diet. We have had the report of the NCPE, which the HSE was considering. We have had two recommendations against sapropterin dihydrochloride, Kuvan, in the past nine years. A meeting was...